1 Plasma proteomics reveals markers of metabolic stress in HIV infected children

with severe acute malnutrition

- 4 Gerard Bryan Gonzales^{1,2*}, James M Njunge^{3,4}, Bonface M Gichuki^{3,4}, Bijun Wen^{5,6}, Isabel
- 5 Potani³, Wieger Voskuijl^{3,7,8}, Robert H J Bandsma^{3,5,6}, James A Berkley^{3,4,9}
- 1. Department of Gastroenterology, Faculty of Medicine and Health Sciences, Ghent
- 7 University, Ghent, Belgium
- 8 2. VIB Inflammation Research Centre, Ghent, Belgium
- 9 3. The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya
- 4. KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya
- 5. Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario,
- 12 Canada

3

- 6. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
- 14 Toronto, Canada
- 15 7. Global Child Health Group, Emma Children's Hospital, Amsterdam University
- Medical Centres, Amsterdam, the Netherlands
- 17 8. Amsterdam Institute for Global Health and Development, Department of Global
- 18 Health, Amsterdam University Medical Centres, Amsterdam, The Netherlands
- 9. Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine,
- 20 University of Oxford, Oxford, UK
- 22 *Correspondence to:

- 23 Gerard Bryan Gonzales, PhD
- 24 Email: Gerard.gonzales@ugent.be

Abstract (word count = 195)

HIV infection affects up to 30% of children presenting with severe acute malnutrition (SAM) in Africa and is associated with increased mortality. Children with SAM are treated similarly regardless of HIV status, although mechanisms of nutritional recovery in HIV and/or SAM are not well understood. We performed a secondary analysis of a clinical trial and plasma proteomics data among children with complicated SAM in Kenya and Malawi. Compared to children with SAM without HIV (n = 113), HIV-infected children (n = 54) had evidence (false discovery rate (FDR) corrected p<0.05) of metabolic stress, including enriched pathways related to inflammation and lipid metabolism. Moreover, we observed reduced plasma levels of zinc- α -2-glycoprotein, butyrylcholinesterase, and increased levels of complement C2 resembling findings in metabolic syndrome, diabetes and other non-communicable diseases. HIV was also associated (FDR corrected p<0.05) with higher plasma levels of inflammatory chemokines. Considering evidence of biomarkers of metabolic stress, it is of potential concern that our current treatment strategy for SAM regardless of HIV status involves a high-fat therapeutic diet. The results of this study suggest a need for clinical trials of therapeutic foods that meet the specific metabolic needs of children with HIV and SAM.

Keywords: HIV, SAM, lipid metabolism, molecular nutrition

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

Malnutrition, specifically undernutrition in all its forms, remains a global public health burden that accounts for 45% of all death among children under 5 years old ¹. Despite careful monitoring and adherence to guidelines set by the World Health Organization, whilst in general, uncomplicated SAM cases treated in the community do well, up to 25% of children with complicated severe acute malnutrition (SAM) treated in a hospital environment do not survive ²⁻⁵. Furthermore, about one in five children treated for complicated SAM and discharged alive, die in the first year after discharge in low-resource settings ⁶⁻⁸. However, our understanding of the pathophysiology underlying the poor prognosis for these children is surprisingly limited. Infection with the human immunodeficiency virus (HIV) is a common co-morbidity of SAM in sub-Saharan Africa affecting up to 30% of admissions among SAM cases 9. HIV-infected or exposed children are significantly more likely to be stunted, wasted, and underweight ¹⁰. They also more often present with other clinical complications and greater susceptibility to infections, thus further complicating their clinical management, which may include providing more aggressive antimicrobial therapy and higher caloric nutritional intervention 11. Moreover, response to clinical management is also less predictable and less well-understood in HIV-infected children compared to their uninfected counterparts ¹². Although acute opportunistic infections play a key role in the outcome of these children, intestinal pathology including inflammation and malabsorption, and metabolic perturbations may also be present. However, mechanisms driving poor nutritional recovery of children with HIV even when detected co-morbidities are treated remain poorly understood ¹².

We hypothesised that inflammatory, metabolic and other pathways which are likely to be involved in the response to infection, survival and nutritional recovery differ between children with SAM with and without HIV. We conducted a secondary analysis of clinical data and biological samples from a randomised clinical trial in Kenya and Malawi ¹³. **Results Patient characteristics** Table 1 presents the baseline characteristics of the children in the randomised trial. A total of 843 complicated SAM children were recruited for the randomised trial, of which 179 (22%) patients were HIV(+). Age was higher and MUAC was lower in HIV(+) children than HIV(-) counterparts. Most HIV cases were found in Malawi. Sex and the presence of oedema were not associated with HIV status. Mortality was more than 2 times higher among in HIV(+) compared to HIV(-) (p < 0.001). Children whose HIV status were unknown had the highest mortality of 34%, which indicates bias due to frequent death before testing could be undertaken or refusal of testing when a child was more severely ill. Among HIV(+), 33% were already receiving an anti-retroviral treatment (ART) regime:

84

53/179 (30%) on highly active antiretroviral therapy (HAART), and 7/179 (4%) on

Nevirapine only. About half of the children (90/179) were naïve for ART whereas HIV

treatment status was unknown for 16% (29/179). Mortality was not significantly different

among children on HAART, ART naïve and children with unknown HIV treatment status

(Supplementary Table 1).

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

85

86

87

88

89

90

92

91 HIV is associated with increased inflammatory and immune response, dysregulated lipid

metabolism, and increased proteolysis in children with SAM

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

Among the children included in the proteomics study, 54 were HIV (+) and 113 were HIV(-) (Table 2). In this sub-population, age, sex and the presence of oedema were not significantly associated with HIV. HIV(+) children also had significantly lower MUAC and higher mortality than HIV(-) children. A total of 204 circulating proteins were annotated and compared between children with and without HIV infection. Of these, levels of 42 proteins were found to be significantly associated with HIV status in the initial univariate analysis (Figure 1A) (Supplementary Table 2). Specifically, HIV(+) was associated with higher circulating levels of immunoglobulins, inflammatory proteins such as calprotectin (S100 calcium binding protein A8 and S100 calcium binding protein A9), complement proteins, and proteins related to host response to infection (i.e. lipopolysaccharide binding protein, galectin 3 binding protein and CD5 molecule-like protein). Enrichment analysis suggested that HIV(+) children had increased complement activation and immune response, and inflammatory responses than HIV(-) children. Neutrophil aggregation and chemokine production appeared to be the pathways most highly enriched in HIV(+) compared to HIV(-) SAM children. To substantiate these results, we quantified chemokine and cytokine levels in plasma. As shown, most chemokines had the tendency to be associated with HIV infection, where elevated plasma concentration of 12 were significantly associated with HIV status in SAM children (Figure 1B), namely: monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1 beta (MIP1b, CCL4), granulocyte colony-stimulating factor (GCSF), interleukin 1 beta (IL1b), tumour necrosis factor alpha (TNFa), interleukins 2,5,7, 8 and 15 (IL2, 5, 7, 8, 15), interleukin 12 subunit beta (IL12p40), interferon gamma-induced protein 10 (IP-10), and interleukin-1 receptor antagonist (IL-1RA).

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

Out of the 43 differentially expressed proteins, three proteins were found to be negatively associated with HIV status on initial univariate analysis, namely: adiponectin, kininogen-1 and peptidase inhibitor 16. Among HIV(+) children, there were no statistically significant associations with receiving HAART (n = 53) compared to ART naïve (n = 90) children (data not shown), recognising our study was not powered for this comparison. Furthermore, sensitivity analysis to address the possibility of HIV maternal antibodies in younger children, showed no significant interaction of age above or below 18 months and individual proteins plasma levels towards HIV status, although power to detect was limited. The weighted EN model extracted 73 circulating proteins (Figure 2A) that are associated with HIV status with AUROC = 0.97 [95% CI: 0.95 - 0.99] (Figure 2B) and misclassification error rate of 2.4%. Optimism-adjusted validated AUROC after bootstrapping was 0.90 [95% CI: 0.90 – 0.902], indicating a robust model. Pathway enrichment analysis highlighted that apart from increased immune response, HIV(+) children with SAM had increased proteolysis and lipid mobilisation, specifically increased very low-density lipoprotein assembly, indicating metabolic dysregulation related to cholesterol and triglyceride metabolism among HIV(+) patients (Figure 2D). After 2000 bootstrap iterations during bootstrap validation, 3 proteins were consistently extracted by the EN model >80% of the time (Figure 2D), namely: butyrylcholinesterase (BChE), complement C2 and zinc-α-2-glycoprotein (ZAG), indicating that these 3 proteins are likely to be the most important features associated with HIV in children with complicated SAM. Weighted logistic regression model of these 3 proteins showed good discrimination of HIV status (AUROC = 0.80 [95% CI: 0.74 - 0.87]) (Figure 2E).

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

Discussion In this study, we report plasma proteomic differences associated with HIV status, suggesting that HIV imposes additional metabolic and inflammatory insults among HIV(+) children with SAM. Our results show that pathways involved in inflammatory response, complement cascade activation and lipid metabolism dysregulation are associated with HIV status. Circulating levels of several plasma chemokines were also found to be higher in HIV(+) among children with SAM. Greater inflammatory responses in these children could be related to the higher inpatient mortality of HIV(+) compared to HIV(-) children with SAM. An earlier metabolomics study in Uganda reported reduced serum levels of adiponectin and leptin, whereas serum triglycerides, ketones and even-chain acylcarnitines were higher in HIV(+) children with SAM indicating perturbed lipid metabolism ¹⁴. Our current study therefore concurs with this finding, as we also found reduced plasma levels of adiponectin in HIV(+) SAM children compared to HIV(-) SAM children, along with upregulation of pathways involved in lipid transport and metabolism, specifically very low-density lipoprotein assembly. Using optimism-adjusted bootstrap validation of the EN model, we found 3 proteins: complement c2, BChE and ZAG robustly distinguished HIV(+) from HIV(-) in children with SAM, demonstrating the ability of multivariate analysis techniques, such as EN, to uncover underlying relationships between protein markers which would be difficult to identify when analysed individually. The activation of the complement system during HIV infection has been previously discussed at length, which is associated with the increased cellular invasion of HIV in cells ¹⁵⁻¹⁷.

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

On the other hand, BChE is a protein synthesized in the liver and abundant in plasma, which hydrolyses acetylcholine. Although very similar to its sister protein, acetylcholinesterase, biological functions of BChE appear to be more varied but less understood ¹⁸. In a recent study in China, low circulating BChE was found to be highly associated with HIV severity, was predictive of mortality in adults, and was proposed as a plausible strategy for severity classification among adults with HIV ¹⁹. BChE is also reported to be reduced in SAM, stress and inflammation ²⁰. In animal studies, BChE deficiency was found to strongly affect fat metabolism and promotes hepatic lipid accumulation ²¹. Serum BChE levels have been found to have a significant negative correlation with serum total cholesterol and serum low-densitylipoprotein cholesterol among people with diabetes mellitus ²². ZAG is a newly characterized adipokine that is involved in lipolysis, body weight regulation and may also be involved in the development of insulin resistance ²³. Reduction in plasma levels of ZAG was previously reported to be implicated in dyslipidaemia in HIV(+) adults under ART treatment ²³. Reduced circulating levels of ZAG has also been found among adults with clinically diagnosed metabolic syndrome, based on guidelines of the United States National Cholesterol Education Program (NCEP) Expert Panel Adult Treatment Panel (ATP) III criteria 24. Serum ZAG levels have been reported lower among adults with impaired glucose tolerance and type 2 diabetes mellitus ²⁵. Taken together, our results therefore suggest that children with both HIV and SAM manifest hallmarks of metabolic stress similar to those occurring in metabolic syndrome and other non-communicable diseases (NCD). This study is the first proteomics investigation on the interaction between HIV and SAM. In summary, our results, which together with the previously published metabolomics study ¹⁴, strengthens evidence on the increased metabolic stress and altered metabolic response among children living with both HIV and SAM. Our results also concur with previous studies that reported elevated metabolic stress among non-malnourished adults living with HIV leading to increased prevalence or risk for metabolic syndrome, cardiovascular diseases, diabetes and other non-communicable diseases ²⁶⁻³².

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

Metabolic abnormalities have previously been reported to be attributed HAART use among HIV(+) patients ³³. In a recent systematic review, use of 2 classes of HAART, protease inhibitors and nonnucleoside reverse transcriptase inhibitors, has been found to be associated with abnormalities in plasma lipid profiles ³⁴. However, dysregulation in lipid metabolism has also been reported in HAART-naïve patients, which indicates that HIV infection alone cause lipid metabolism perturbations. An earlier longitudinal study of 50 men in the USA reported notable declines in serum total cholesterol after HIV infection compared to results of blood analysis from last seronegative visit. Large increases in total cholesterol and low-density lipoproteins (LDL) were detected after HAART initiation ³⁵. However, many other studies reported increases in total cholesterol among HIV-infected patients naïve to HAART. For instance, in a study of ART-naïve HIV-infected adults in Ethiopia, malnutrition and lipid abnormalities (specifically total cholesterol) were associated with CD4+ T cell counts ³⁶. In in vitro studies, transfection of a T-cell (RH9) with HIV led to the enhanced production of free fatty acids and LDL ³⁷. Furthermore, monocytes isolated from HIV-infected patients both taking HAART and HAART-naïve, were found to have altered expression patters of receptors linked with lipid metabolism (i.e. FXR, PXR, PPARα, GR, RARα and RXR) compared to monocytes of HIV-uninfected controls ³⁸. For our study however, we are unable to ascertain whether the lipid metabolism dysregulation we observed is due primarily on the viral load itself or the use of HAART due to lack of power for this sub-analysis. Majority of the participants subjected to proteomics analysis were HAART-naïve (50%), where 26% were on

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

HAART, 6% were on Nevirapine alone and we had no data on treatment of 18% of the patients (Table 2). In all these studies cited, authors argue to need for monitoring of lipid profiles in HIV-infected populations. Hence, lipid monitoring may also inform nutritional and clinical recovery of children with SAM and HIV and could be implemented to improve clinical care for these children. However, despite our knowledge that HIV-infected populations have altered metabolic requirements compared to HIV-uninfected counterparts, WHO guidelines for the nutritional management for SAM are globally the same regardless of HIV status, which is summarized in Table 3 39. Nutritional management for in-patient children with SAM involves provision of a low-protein, low-fat milk-based food, F75, every three hours. F75 is used during clinical stabilization occurring during the first few days after admission and is not intended for weight gain. Once the children are clinically stabilized and are able to tolerate the milk/solute load, children are transitioned to F100, a higher-calorie, high-fat milk intended to boost weight gain or to Ready-to-Use Therapeutic Food (RUTF), a peanut-based calorie-dense diet. Upon discharge from in-patient care, children are referred to community based nutritional therapeutic centres where they are provided with RUTF on a 2 weekly basis. Considering evidence of biomarkers of metabolic syndrome and NCD in HIV(+) children with SAM, it is of potential concern that our current treatment strategy involves a high-fat therapeutic diet. About 50% of much needed calories during the growth catch-up phase are supplied as lipids, which HIV(+) children may not be able to efficiently assimilate. Alterations in lipid metabolism in HIV(+) children with SAM may also mean that the high amounts of dietary lipids could be deposited as ectopic fat in the liver and muscle, predisposing to insulin resistance, diabetes, cardiovascular problems and other NCDs later in

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

life. Although long-term metabolic follow-up studies could be done for HIV(+) children previously treated for either complicated and uncomplicated SAM, significant barriers are the high mortality rate in earlier studies of HIV(+) children with SAM, cost and difficulty tracing them years later. The results of this study indicate a need for clinical trials of F100 or RUTF modified to meet the expected metabolic needs of HIV(+) children with SAM. This could initially be done in relatively small groups with outcomes that include measuring metabolic stress. Several studies on nutritional intervention strategies among HIV-infected adults have been reported. For instance, a study in the USA showed that dietary fat intake, specifically saturated fats, was significantly associated with hypertriglyceridemia among HIV-infected adults (18 – 60 years) 40. Moreover, in a preclinical model, high saturated fat consumption was found to accelerate immunodeficiency virus disease progression in macaques, specifically increased mortality hazard and circulating levels of pro-inflammatory cytokines, especially IL8 ⁴¹, which has been previously reported to be associated with lipodystrophy among HIV patients ⁴². In our study, we also found a significant association between high plasma IL8 concentration and HIV in SAM children. Hence, modifying the saturated fat composition of the milk-based F75 and F100 could potentially lower metabolic stress. The European Society for Parenteral and Enteral Nutrition (ESPEN) have given a grade A recommendation for the use of medium-chain triglyceride (MCT)-based diet on HIV(+) patients with diarrhoea and severe undernutrition in its 2006 ESPEN Guidelines on Enteral Nutrition ⁴³. Grade A recommendations are given to strategies based on meta-analysis or at least one randomised control trial. In this case, the recommendation was based on a prospective, randomized double-blind comparative trial on 24 adult patients with HIV and

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

diarrhoea of more than 4-wk duration, fat malabsorption, and loss of 10-20% of ideal body weight 44. In this study, the authors found improved outcomes from diarrhoea and fat malabsorption from MCT than long-chain triglyceride-based diet among HIV(+) adults. Lastly, the long-term metabolic effect of nutritional intervention strategies for SAM still remains unresolved. Most specifically, the potential metabolic stress associated with the rapid weight gain during the nutritional rehabilitation phase after SAM and its implications on nutritional outcomes during adulthood demands urgent research attention, especially for HIV(+) children with SAM. Limitations of this study include absence of data on viral load and CD4+ counts of the patients, which could provide a deeper understanding of the results. Furthermore, in this study, we did not find association between oedematous malnutrition and HIV status, although several studies have a found higher HIV prevalence among non-oedematous children with SAM ⁴⁵⁻⁴⁷. In our study however, we found high in-patient mortality rate (16/46, 34%) among children with unknown HIV status, where 39/46 (85%) had non-oedematous SAM. Considering the high rate of mortality, these children may have been HIV(+). This highlights the need for earlier HIV screening among children with SAM. Conclusion Plasma proteomics reveals that HIV(+) children with SAM manifest hallmarks of metabolic stress similar to those observed in non-communicable diseases. This could be related to the poor nutritional recovery and high mortality of HIV(+) children with SAM despite clinical and nutritional intervention. The results of this study indicate a need for clinical trials modifying the composition of F100 or RUTF to meet the specific metabolic needs of HIV(+)

children with SAM during rehabilitation phase. This could initially be done in relatively small groups with outcomes that include measuring metabolic stress.

Methods

Patient recruitment and study design

This is a secondary analysis of a nested case control study from a randomised controlled trial (NCT02246296), which tested the effect of a lactose-free, low-carbohydrate F75 milk to limit carbohydrate malabsorption, diarrhoea and refeeding syndrome among children hospitalized for complicated SAM at Queen Elizabeth Central Hospital in Blantyre, Malawi, Kilifi County Hospital and Coast General Hospital, Mombasa, Kenya ¹³. Children aged 6 months to 13 years were eligible for enrolment into the trial at admission to hospital if they had SAM, defined as: mid-upper arm circumference (MUAC) <11.5cm or weight-for-height Z score <-3 if younger than 5 years of age, BMI Z score <-3 if older than 5 years, or oedematous malnutrition at any age and had medical complications or failing an appetite test, as defined by WHO guidelines ⁴⁸. Children were excluded if they had a known allergy to milk products and did not provide consent. Biological samples were obtained before the children received the randomised treatment irrespective of HIV status. Unless a child's HIV positive status was documented, HIV status was assessed by offering an antibody test at admission plus appropriate counseling. For this analysis, patients that tested positive on an HIV antibody test were considered HIV(+) and children with missing or declined HIV test were excluded.

The nested case-control study was designed to investigate inpatient mortality for which proteomic, cytokine, and chemokine data was generated using plasma samples collected at admission during enrolment to the trial. To compare the proteomic profiles between HIV affected and non-affected children with SAM, we used data from a nested case-control study

to investigate inpatient mortality during the trial including 79 deaths and 88 children that were clinically stabilized and discharged from the hospital matched by site of recruitment. For this analysis, all observations from the proteomics dataset were included and the analysis was designed to help overcome selection bias, as given in detail below.

Proteomics, cytokine and chemokine analysis

Untargeted proteomics and targeted cytokines and chemokines analysis of plasma samples were performed following methods described previously ⁴⁹. The targeted protein panel included: epidermal growth factor (EGF); eotaxin; granulocyte-colony stimulating factor (GCSF); granulocyte-macrophage colony-stimulating factor (GMCSF); interferon alpha-2 (IFNa2); interferon gamma (IFNg); interleukins 10, 12p40, 12p70, 13, 15, 17A, 1a, 1b, 1RA, 2 to 8; interferon gamma-induced protein 10 (IP10); monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1 alpha and beta (MIP1a & b); tumour necrosis factor alpha (TNFa) and beta (TNFb); and vascular endothelial growth factor (VEGF).

Data analysis

Data analyses were performed using R v3.5 ⁵⁰. Analysis of the prevalence of HIV(+), nutritional status and their associations with inpatient mortality utilised the entire trial dataset (N=843). Analysis of categorical data was performed using Fisher's test and generalised linear models for continuous outcomes. Logistic regression was used to analyse binary outcomes adjusting for age, sex, presence of oedema, and site of recruitment. These associations were also adjusted for MUAC. As a sensitivity analysis to address the possibility of confounding due to HIV maternal antibodies in younger children, a test of interaction between age above or below 18 months and individual proteins towards HIV status was performed.

The proteomics, cytokines and chemokines analyses were secondary analyses of data collected from a nested case-control study with inpatient mortality as its primary outcome, hence with strong selection bias. The analysis for the association between HIV status and individual proteins was therefore performed using logistic regression analysis with inverse probability weighting (IPW) to correct for selection bias ⁵¹⁻⁵⁴. Weights (*w*) were calculated as suggested by Samuelsen ⁵² wherein the weight for each observation selected into the nested case-control study was computed as the inverse of the probability of being selected for the nested study from the main clinical trial. The probability of inclusion was therefore calculated as:

354
$$p(i) = \frac{1}{1 + e^{-(\beta_0 + \beta_1 x_1 + \beta_2 x_2 \dots + \beta_n x_n)}};$$

where p(i) is the probability of inclusion in the nested case-control study and x1, x2 ... xn are HIV status, sex, age, presence of oedema, mid-upper arm circumference, and site of recruitment of the i-th observation (child) based on the entire trial population. Inverse probability weight is therefore:

$$360 w(i) = \frac{1}{p(i)}$$

Differences in individual proteins abundances were considered statistically significant when p<0.05 after adjustment for multiple comparisons using Benjamini-Hochberg false discovery rate (FDR) ⁵⁵.

Multivariate analysis was undertaken in order to determine several proteins that are collectively associated with HIV status, some of which may not be significantly associated to

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

HIV independently. This was performed using a weighted elastic net (EN) model implemented using the "glmnet" package in R ⁵⁶. EN is a penalized regression approach that was developed to help overcome problems caused by high dimensional data. It is an integration of two regularized approaches, ridge regression and least absolute shrinkage and selection operator (LASSO), wherein the contribution of each of these models to the final EN model is controlled by the α parameter ^{56,57}. The strong penalization imposed by LASSO draws coefficients to zero thereby eliminating non-predictive proteins features, whereas ridge regression addresses potential multi-collinearity problems in high-dimensional data ^{56,57}. Weighted EN model generation was performed with HIV status as outcome, protein profile as predictors, and w as observation weights. The penalization parameter lambda, which influences the shrinkage of variable coefficients to zero thus eliminating some noncontributing variables, was determined by estimating the area under the receiver operator curve (ROC) of the population using ten-fold cross validation. Several alpha parameter values were assessed and a final value of 0.85 was taken to achieve a compromise between predictive ability and fewer number of features extracted. The final lambda parameter was based on the value which gave the highest area under the ROC (AUROC) value. Proteins with significant association with HIV status after correction for false discovery and those extracted by the EN model were then uploaded to The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 Bioinformatics Resource ⁵⁸ to assess the Gene ontology (GO) enriched pathways of the differentially expressed proteins. EN model validity was judged based on the AUROC and misclassification error rate. The fitted EN model performance measured as optimism-corrected AUC was validated using bootstrap, following the procedure of Smith et al. ⁵⁹. Bootstrapping was performed on 2000 iterations using the "BootValidation" package in R. Protein features extracted at least 80% of all iterations by the bootstrap EN model were then considered to be the most relevant protein biomarkers. To test how well these proteins can discriminate HIV status, they were then fitted on a weighted logistic regression with HIV as outcome.

Visualisation of significantly enriched GO terms

Bubble plots were used to visualise the significantly enriched pathways (p<0.05 after adjustment for FDR) obtained from DAVID. The p-values in DAVID were obtained using a modified Fisher's exact test ⁶⁰. The y-axis represents the fold enrichment which indicates the magnitude of the enrichment, as calculated in DAVID. Fold enrichment is defined as:

fold enrichment =
$$\frac{(m/n)}{M/N}$$
,

where m is the number of proteins significantly associated with HIV status or proteins extracted by the EN model that belong to a particular pathway, while M is the total number of proteins belonging to the same pathway. Variable n is the number of all proteins significantly associated with HIV status or extracted by the EN model and N is the total number of all proteins in the human background. Therefore, a fold enrichment of 10 indicates that 10% of the proteins significantly associated with HIV status belong to a particular pathway, and 1% of all annotated proteins in the human background belongs to the same pathway 60 . However, the proponents of this metric warn that big fold enrichments could be obtained from a small number of proteins, which could be due to small n or pathways with fewer members.

The x-axis on the hand represents the enrichment z-score for a particular pathway ⁶¹, which is calculated as follows:

$$z - score = \frac{(up - down)}{\sqrt{count}};$$

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

where up is the total number of proteins upregulated, down is the total number of proteins downregulated, and *count* is the total number of proteins in the input which belongs to a particular pathway. Variables up and down were based on the weighted logistic regression for each individual protein. Hence, if 5 proteins belonging to pathway x were upregulated and 2 were downregulated, the z-score for pathway x would be: $(5-2)/\sqrt{7} = 1.13$. A positive z-score indicates that the particular pathway is overall upregulated in HIV(+), whereas a negative zscore indicates an overall downregulation ⁶¹. **Funding Sources** The original clinical trial was supported by the Thrasher Fund (grant number: 9403), awarded to JAB. GBG is a postdoctoral fellow of the Research Foundation – Flanders (FWO). The Ghent University -VLIR-UOS Global Minds Fund supported the travel of GBG to Kenya. JAB and JMN are currently supported by the Bill & Melinda Gates Foundation within the Childhood Acute Illness and Nutrition (CHAIN) Network (grant OPP1131320). JAB is currently supported by the MRC/DfID/Wellcome Trust Joint Global Health Trials scheme (grant MR/M007367/1). The funders had no role in the design, conduct, analysis, or writing of this manuscript. **Declaration of Interests** The authors declare that we do not have any conflicts of interest. Study approvals The secondary analyses of the trial were approved by the Kenyan national ethics committee, KEMRI- SERU (KEMRI/RES/7/3/1). The trial was registered at clinicaltrials.gov (NCT02246296).

Author contributions

443

444

449

450

- 445 GBG, JMN and JAB designed the study and data analysis. JMN and BG performed the
- proteomics analysis. GBG performed data analysis. BW, RB, WV, IP and JAB were involved
- in the clinical aspects of the study. GBG wrote the initial drafts of the manuscript and all
- authors contributed to editing and improving the manuscript.

References

- Black, R. E. *et al.* Maternal and child undernutrition and overweight in low-income and middle-income countries. *The Lancet* **382**, 427-451, doi:10.1016/S0140-6736(13)60937-X (2013).
- Heikens, G. T. *et al.* Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence. *Lancet* **371**, 1305-1307, doi:10.1016/s0140-6736(08)60565-6 (2008).
- 457 3 Irena, A. H., Mwambazi, M. & Mulenga, V. Diarrhea is a Major killer of Children with Severe Acute Malnutrition Admitted to Inpatient Set-up in Lusaka, Zambia. *Nutr.* 459 *J.* **10**, 110-110, doi:10.1186/1475-2891-10-110 (2011).
- 460 4 Maitland, K. *et al.* Children with Severe Malnutrition: Can Those at Highest Risk of Death Be Identified with the WHO Protocol? *PLoS Med.* **3**, e500, doi:10.1371/journal.pmed.0030500 (2006).
- Hossain, M. *et al.* Efficacy of World Health Organization guideline in facility-based reduction of mortality in severely malnourished children from low and middle income countries: A systematic review and meta-analysis. *J. Paediatr. Child Health* **53**, 474-479, doi:10.1111/jpc.13443 (2017).
- Kerac, M. *et al.* Follow-Up of Post-Discharge Growth and Mortality after Treatment
 for Severe Acute Malnutrition (FuSAM Study): A Prospective Cohort Study. *PLOS ONE* 9, e96030, doi:10.1371/journal.pone.0096030 (2014).
- Berkley, J. A. *et al.* Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial. *The Lancet. Global health* **4**, e464-473, doi:10.1016/s2214-109x(16)30096-1 (2016).
- Nemetchek, B. *et al.* Paediatric postdischarge mortality in developing countries: a systematic review. *BMJ Open* **8**, e023445, doi:10.1136/bmjopen-2018-023445 (2018).
- Fergusson, P. & Tomkins, A. HIV prevalence and mortality among children undergoing treatment for severe acute malnutrition in sub-Saharan Africa: a systematic review and meta-analysis. *Trans. R. Soc. Trop. Med. Hyg.* **103**, 541-548, doi:10.1016/j.trstmh.2008.10.029 (2009).
- Ndirangu, M., Wariero, J. O., Sachs, S. E., Masibo, P. & Deckelbaum, R. J. Nutritional status of under-five children in HIV-affected households in western Kenya. Food Nutr. Bull. 32, 159-167, doi:10.1177/156482651103200208 (2011).

- Rose, A. M., Hall, C. S. & Martinez-Alier, N. Aetiology and management of malnutrition in HIV-positive children. *Arch. Dis. Child.* **99**, 546-551, doi:10.1136/archdischild-2012-303348 (2014).
- Trehan, I., O'Hare, B. A., Phiri, A. & Heikens, G. T. Challenges in the Management of HIV-Infected Malnourished Children in Sub-Saharan Africa. *AIDS Res. Treat.* **2012**, 8, doi:10.1155/2012/790786 (2012).
- 489 13 Bandsma, R. H. J. et al. A reduced-carbohydrate and lactose-free formulation for 490 stabilization among hospitalized children with severe acute malnutrition: A double-491 blind, randomized controlled trial. **PLoS** Med. **16**, e1002747, 492 doi:10.1371/journal.pmed.1002747 (2019).
- 493 14 Mody, A. *et al.* Effects of HIV infection on the metabolic and hormonal status of children with severe acute malnutrition. *PLoS One* **9**, e102233, doi:10.1371/journal.pone.0102233 (2014).
- Tacnet-Delorme, P. *et al.* In Vitro Analysis of Complement-Dependent HIV-1 Cell Infection Using a Model System. *The Journal of Immunology* **162**, 4088 (1999).
- 498 16 Stoiber, H., Kacani, L., Speth, C., Würzner, R. & Dierich, M. P. The supportive role of complement in HIV pathogenesis. *Immunol. Rev.* **180**, 168-176, doi:10.1034/j.1600-065X.2001.1800115.x (2001).
- 501 17 Stoiber, H., Speth, C. & Dierich, M. P. Role of complement in the control of HIV dynamics and pathogenesis. *Vaccine* 21, S77-S82, doi:https://doi.org/10.1016/S0264-410X(03)00203-2 (2003).
- 504 18 Oliveira, J. d. *et al.* Effect of BCHE single nucleotide polymorphisms on lipid metabolism markers in women. *Genet. Mol. Biol.* **40**, 408-414, doi:10.1590/1678-4685-GMB-2016-0123 (2017).
- 507 19 Xu, L. *et al.* Butyrylcholinesterase Levels on Admission Predict Severity and 12-508 Month Mortality in Hospitalized AIDS Patients. *Mediators Inflamm.* **2018**, 5201652, 509 doi:10.1155/2018/5201652 (2018).
- Santarpia, L., Grandone, I., Contaldo, F. & Pasanisi, F. Butyrylcholinesterase as a prognostic marker: a review of the literature. *Journal of cachexia, sarcopenia and muscle* **4**, 31-39, doi:10.1007/s13539-012-0083-5 (2013).
- Chen, V. P. *et al.* Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet. *Endocrinology* **157**, 3086-3095, doi:10.1210/en.2016-1166 (2016).
- 516 22 Sridhar, G. *et al.* Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. *Lipids Health Dis.* **4**, 18, doi:10.1186/1476-518 511x-4-18 (2005).
- Ceperuelo-Mallafre, V. *et al.* Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs. *HIV Med.* **13**, 297-303, doi:10.1111/j.1468-1293.2011.00976.x (2012).
- Lei, L. *et al.* Circulating zinc-α2-glycoprotein levels are low in newly diagnosed patients with metabolic syndrome and correlate with adiponectin. *Nutr. Metab. (Lond.)* **14**, 53, doi:10.1186/s12986-017-0210-6 (2017).
- Yang, M. *et al.* Zinc-α2-glycoprotein is associated with insulin resistance in humans
 and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration:
 cross-sectional and interventional studies in normal subjects, insulin-resistant subjects,
- and subjects with newly diagnosed diabetes. *Diabetes care* **36**, 1074-1082, doi:10.2337/dc12-0940 (2013).
- Bastard, J. P. *et al.* Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients. *Diabetes Metab.*, doi:10.1016/j.diabet.2019.02.008 (2019).

- 533 27 Nix, L. M. & Tien, P. C. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. *Curr. HIV/AIDS Rep.* **11**, 271-278, doi:10.1007/s11904-014-0219-7 (2014).
- 535 28 Sobieszczyk, M. E. *et al.* Metabolic Syndrome After HIV Acquisition in South African Women. *J. Acquir. Immune Defic. Syndr.* **73**, 438-445, doi:10.1097/qai.000000000001123 (2016).
- Policarpo, S., Rodrigues, T., Moreira, A. C. & Valadas, E. Cardiovascular risk in HIVinfected individuals: A comparison of three risk prediction algorithms. *Rev. Port. Cardiol.* **38**, 463-470, doi:10.1016/j.repc.2019.08.002 (2019).
- Lagathu, C. *et al.* Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. *Expert Opin. Drug Saf.* **18**, 829-840, doi:10.1080/14740338.2019.1644317 (2019).
- Sears, S. *et al.* Metabolic Syndrome Among People Living with HIV Receiving Medical Care in Southern United States: Prevalence and Risk Factors. *AIDS Behav.*, doi:10.1007/s10461-019-02487-8 (2019).
- Seth, A. & Sherman, K. E. Fatty liver disease in persons with HIV infection. *Top. Antivir. Med.* **27**, 75-82 (2019).
- Palios, J., Kadoglou, N. P. E. & Lampropoulos, S. The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. *Exp. Diabetes Res.* **2012**, 103063-103063, doi:10.1155/2012/103063 (2012).
- 553 34 Silva, B., Peixoto, G., da Luz, S., de Moraes, S. & Peres, S. Adverse effects of chronic 554 treatment with the Main subclasses of highly active antiretroviral therapy: a systematic 555 review. *HIV Med.* **20**, 429-438, doi:10.1111/hiv.12733 (2019).
- 556 35 Riddler, S. A. *et al.* Impact of HIV Infection and HAART on Serum Lipids in Men. *JAMA* **289**, 2978-2982, doi:10.1001/jama.289.22.2978 (2003).
- Adal, M., Howe, R., Kassa, D., Aseffa, A. & Petros, B. Malnutrition and lipid abnormalities in antiretroviral naïve HIV-infected adults in Addis Ababa: A cross-sectional study. *PLOS ONE* **13**, e0195942, doi:10.1371/journal.pone.0195942 (2018).
- 37 561 Rasheed, S., Yan, J. S., Lau, A. & Chan, A. S. HIV Replication Enhances Production 562 of Free Fatty Acids, Low Density Lipoproteins and Many Key Proteins Involved in 563 Lipid Metabolism: A **Proteomics** Study. **PLOS** ONE e3003, 564 doi:10.1371/journal.pone.0003003 (2008).
- Renga, B. *et al.* HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes. *BMC Infect. Dis.* **12**, 274, doi:10.1186/1471-2334-12-274 (2012).
- Trehan, I. & Manary, M. J. Management of severe acute malnutrition in low-income and middle-income countries. *Arch. Dis. Child.* **100**, 283-287, doi:10.1136/archdischild-2014-306026 (2015).
- Joy, T. *et al.* Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. *AIDS (London, England)* **21**, 1591-1600, doi:10.1097/QAD.0b013e32823644ff (2007).
- 574 41 Mansfield, K. G. *et al.* A diet high in saturated fat and cholesterol accelerates simian 575 immunodeficiency virus disease progression. *J. Infect. Dis.* **196**, 1202-1210, 576 doi:10.1086/521680 (2007).
- 577 42 Lindegaard, B. *et al.* Adipose tissue expression of IL-18 and HIV-associated lipodystrophy. *AIDS* **18**, 1956-1958, doi:10.1097/00002030-200409240-00013 (2004).
- Ockenga, J. *et al.* ESPEN Guidelines on Enteral Nutrition: Wasting in HIV and other chronic infectious diseases. *Clin. Nutr.* **25**, 319-329, doi:10.1016/j.clnu.2006.01.016 (2006).

- Wanke, C. A. *et al.* A medium chain triglyceride-based diet in patients with HIV and chronic diarrhea reduces diarrhea and malabsorption: A prospective, controlled trial. *Nutrition* **12**, 766-771, doi:https://doi.org/10.1016/S0899-9007(96)00221-3 (1996).
- Amadi, B. *et al.* Intestinal and systemic infection, HIV, and mortality in Zambian children with persistent diarrhea and malnutrition. *J. Pediatr. Gastroenterol. Nutr.* **32**, 550-554, doi:10.1097/00005176-200105000-00011 (2001).
- Kessler, L., Daley, H., Malenga, G. & Graham, S. The impact of HIV infection on the clinical presentation of severe malnutrition in children at QECH. *Malawi medical journal: the journal of Medical Association of Malawi* 13, 30-33 (2001).
- Musoke, P. M. & Fergusson, P. Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings. *The American journal of clinical nutrition* **94**, 1716S-1720S, doi:10.3945/ajcn.111.018374 (2011).
- 595 48 WHO. Management of severe malnutrition: a manual for physicians and other senior 596 health workers, http://apps.who.int/iris/bitstream/10665/41999/1/a57361.pdf 597 (1999).
- Njunge, J. M. *et al.* Biomarkers of post-discharge mortality among children with complicated severe acute malnutrition. *Sci. Rep.* **9**, 5981, doi:10.1038/s41598-019-42436-y (2019).
- R Core Team. *R: A language and environment for statistical computing. R Foundation for Statistical Computing*, https://www.R-project.org/ (2017).
- 603 51 Kim, R. S. & Kaplan, R. C. Analysis of secondary outcomes in nested case-control study designs. *Stat. Med.* **33**, 4215-4226, doi:10.1002/sim.6231 (2014).
- Samuelsen, S. O. A Pseudolikelihood Approach to Analysis of Nested Case-Control Studies. *Biometrika* **84**, 379-394 (1997).
- 607 53 Pan, Y., Cai, J., Longnecker, M. P. & Zhou, H. Secondary outcome analysis for data from an outcome-dependent sampling design. *Stat. Med.* 37, 2321-2337, doi:10.1002/sim.7672 (2018).
- 54 Jiang, Y., Scott, A. J. & Wild, C. J. Secondary analysis of case-control data. *Stat. Med.* 611 25, 1323-1339, doi:10.1002/sim.2283 (2006).
- Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society*.
 Series B (Methodological) 57, 289-300 (1995).
- Friedman, J. H., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. 2010 33, 22, doi:10.18637/jss.v033.i01 (2010).
- Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. *J. Roy. Stat. Soc. Ser. B. (Stat. Method.)* 67, 301-320, doi:10.1111/j.1467-9868.2005.00503.x
 (2005).
- Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protocols* 4, 44-57, doi:http://www.nature.com/nprot/journal/v4/n1/suppinfo/nprot.2008.211_S1.html
 (2008).
- 59 Smith, G. C. S., Seaman, S. R., Wood, A. M., Royston, P. & White, I. R. Correcting for Optimistic Prediction in Small Data Sets. *Am. J. Epidemiol.* **180**, 318-324, doi:10.1093/aje/kwu140 (2014).
- Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44-57, doi:10.1038/nprot.2008.211 (2009).

Walter, W., Sanchez-Cabo, F. & Ricote, M. GOplot: an R package for visually combining expression data with functional analysis. *Bioinformatics* **31**, 2912-2914, doi:10.1093/bioinformatics/btv300 (2015).

631 632

Figure Legend

635 636 637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663 664

665

666

667

668

Figure 1. Univariate analysis of plasma proteome and individual plasma cytokines associated with HIV. (A) Volcano plot showing several significantly different (FDR adjusted p value < 0.05) proteins and their log2 HIV(+) versus HIV(-) fold change. Red points represent those significantly higher in plasma of HIV(-), blue points significantly enriched in plasma of HIV(+) and orange points significantly higher than 1.5 folds in HIV(+) compared to HIV(-) SAM children. Vertical lines indicate significance level at p = 0.05 and 0.01; horizontal lines indicate more than 1.5 folds enrichment. (B) Log odds plots showing association of chemokine markers analysed using Luminex platform and HIV status. Points indicate log odds ratio for every log increase in plasma protein concentration; bars indicate 95% confidence interval.

Figure 2. Multivariate analysis of plasma proteome associated with HIV. (A) Elastic net (EN) regularized regression lambda parameter optimization curve, optimal lambda parameter was chosen based on the highest area under the receiver operator curve (AUROC); (B) AUROC (0.97 [95% CI: 0.95 – 0.99]) of the EN model generated using the lambda parameter, alpha parameter was set to 0.75, final model extracted 34 protein features, optimism-adjusted bootstrap validation of the generated EN model, validated AUROC = 0.90 [95% CI: 0.90 – 0.90] using 2000 iterations; (C) Gene entology (GO-terms) enrichment analysis of proteins extracted by the EN model. X-axis represents z-scores; y-axis, fold enrichment, and size of the spheres represent the number of proteins involved in the particular pathway. Gold circles represent pathways enriched in HIV(+) whereas blue circles are pathways more associated with HIV(-). The grey circle indicate that there are as much proteins in this pathway that are significantly upregulated and downregulated in HIV. Only significantly enriched pathways (p < 0.05 after FDR adjustment) are plotted. See main text for explanation of the plots. Pathways enriched are identified in the table. (D) Log odds ratio plot of the 3 proteins extracted after bootstrap validation with log odds on the x-axis and bars indicating 95% confidence interval obtained using weighted logistic regression with HIV as outcome variable and the 3 proteins as covariates. Weights used were obtained by inverse probability of treatment weights; (E) Predictive ability of the weighted logistic regression model using the 3 bootstrap validated proteins with HIV as outcome variable, AUROC = 0.80 [95% CI: 0.73 – 0.87]

669 Tables

670

Table 1. Descriptive characteristics of the study participants

-	All	HIV (+)	HIV (-)	Unknown HIV status	<i>p</i> *
n (%)	843	179 (21%)	618 (73%)	46 (5%)	
Median age in months [IQR]	16 [10 – 25]	21 [12 – 31]	16 [10 – 25]	10 [8 – 17]	<0.001
% girls (n)	45% (359)	45% (81)	45% (278)	56% (26)	0.95
Mean MUAC in cm [95% CI]	11.2 [11.1 - 11.3]	10.5 [10.36 - 10.7]	11.4 [11.3 -11.5]	11.2 [10.9 – 11.5]	<0.001
Mean weight-for-age z-score [95% CI]	-4.01 [-4.11 – -3.92]	-4.51 [-4.72 – -4.31]	-3.92 [-4.03 – -3.80]	-3.56 [-3.94 – -3.92]	<0.001
% mortality (n)	15% (127)	26% (47)	10% (64)	34% (16)	<0.001°
% oedematous (n)	31% (264)	30% (54)	33% (203)	15% (7)	0.50
Site					
Coast Provincial General Hospital, Kenya	39% (329)	25% (45)	40% (247)	80% (37)	Reference
Kilifi County Hospital, Kenya	22% (187)	22% (40)	23% (145)	4% (2)	0.08
Queen Elizabeth Central Hospital, Malawi	39% (327)	52% (94)	36% (226)	15% (7)	<0.001

^{*}comparison between HIV(+) and HIV(-); °adjusted for age, sex and site of recruitment

Table 2. Patient characteristics of those subjected to proteomics analysis

	All	HIV (+)	HIV (-)	<i>p</i> *
n	167	54	113	
Median age in months [IQR]	15 [10 – 26]	15 [10 – 26]	15 [10 – 24]	0.433
n girls (%)	76 (45%)	27 (50%)	49 (43%)	0.506
Mean MUAC at admission (cm) [95% CI]	10.9 [10.7 - 11.1]	10.2 [9.8 - 10.5]	11.3 [11.0 - 11.5]	<0.001
n oedematous (%)	49 (29%)	15 (28%)	34 (30%)	0.856
n mortality (%)	79 (47%)	36 (67%)	43 (38%)	<0.001°
Use of antiretroviral medication Naïve highly active antiretroviral therapy (HAART) Nevirapine only Unknown		27 (50%) 14 (26%) 3 (6%) 10 (18%)		

^{*}comparison between HIV(+) and HIV(-), oadjusted for age, sex, site of recruitment, oedema

Table 3. Nutritional management protocol for children with severe acute malnutrition ³⁹

	Stabilization phase	In-patient Rehabilitation phase	Out-patient Rehabilitation phase
	Days 1 - 7	Weeks 2 - 6	Lengths vary depending on site
Complicated SAM	F75	F100	RUTF
Uncomplicated SAM	-	-	RUTF
Composition			
Energy (kcal per 100 mL F75/F100 or 100 g RUTF)	75	100	5.2 – 5.5
Protein (% total energy)	5	12	10 – 12
Fat (% total energy)	32	53	45 - 60

681

682 683 *HAART - highly active antiretroviral therapy; NVP – Nevirapine; # adjusted for age, sex, site and oedema

Supplementary table 2. Association between individual proteins to HIV status

Uniprot accession	Protein code	Protein names	log FC*	p°
P05109	S100A8	Protein S100-A8 (Calgranulin-A) (Calprotectin L1L subunit) (Cystic fibrosis antigen) (CFAG) (Leukocyte L1 complex light chain) (Migration inhibitory factorrelated protein 8) (MRP-8) (p8) (S100 calcium-binding protein A8) (Urinary stone protein band A)	0.56	0.00
P06702	S100A9	Protein S100-A9 (Calgranulin-B) (Calprotectin L1H subunit) (Leukocyte L1 complex heavy chain) (Migration inhibitory factor-related protein 14) (MRP-14) (p14) (S100 calcium-binding protein A9)	0.55	0.00
P01708		Immunoglobulin lambda variable 2-11 (Ig gamma lambda chain V-II region DOT) (Ig lambda chain V-II region BOH) (Ig lambda chain V-II region BUR) (Ig lambda chain V-II region NIG-58) (Ig lambda chain V-II region TRO) (Ig lambda chain V-II region WIN)	0.59	0.01
P04275	VWF	von Willebrand factor (vWF) [Cleaved into: von Willebrand antigen 2 (von Willebrand antigen II)]	0.33	0.01
P01880	IGHD	Immunoglobulin heavy constant delta (Ig delta chain C region) (Ig delta chain C region NIG-65) (Ig delta chain C region WAH)	0.60	0.01
P23083	IGHV1-2	Immunoglobulin heavy variable 1-2 (Ig heavy chain V-I region ND) (Ig heavy chain V-I region V35)	0.60	0.01
P01598		Immunoglobulin kappa variable 1-5 (Ig kappa chain V-I region CAR) (Ig kappa chain V-I region EU) (Ig kappa chain V-I region HK102) (Ig kappa chain V-I region Kue)	0.55	0.01
P80748	IGLV3-21	Immunoglobulin lambda variable 3-21 (Ig lambda chain V-III region LOI) (Ig lambda chain V-V region DEL) (Ig lambda chain V-VII region MOT)	0.58	0.01
P13796	LCP1	Plastin-2 (L-plastin) (LC64P) (Lymphocyte cytosolic protein 1) (LCP-1)	0.28	0.01
P01857	IGHG1	Immunoglobulin heavy constant gamma 1 (Ig gamma-1 chain C region) (Ig gamma-1 chain C region EU) (Ig gamma-1 chain C region KOL) (Ig gamma-1 chain C region NIE)	0.64	0.01
P05362	ICAM1	Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54)	0.28	0.01
P06318		Immunoglobulin lambda variable 6-57 (Ig lambda chain V-VI region AR) (Ig lambda	0.49	0.01

		chain V-VI region EB4) (Ig lambda chain V-VI region NIG-48) (Ig lambda chain V-VI region SUT) (Ig lambda chain V-VI region WLT)		
P18428	LBP	Lipopolysaccharide-binding protein (LBP)	0.31	0.01
P01834	IGKC	Immunoglobulin kappa constant (Ig kappa chain C region) (Ig kappa chain C region AG) (Ig kappa chain C region CUM) (Ig kappa chain C region EU) (Ig kappa chain C region OU) (Ig kappa chain C region TI)	0.69	0.02
P0CG05		Immunoglobulin lambda constant 3 (Ig lambda chain C region DOT) (Ig lambda chain C region NEWM) (Ig lambda-3 chain C regions)	0.67	0.02
P0CG05		Immunoglobulin lambda constant 2 (Ig lambda chain C region Kern) (Ig lambda chain C region NIG-64) (Ig lambda chain C region SH) (Ig lambda chain C region X) (Ig lambda-2 chain C region)	0.67	0.02
B9A064	IGLL5	Immunoglobulin lambda-like polypeptide 5 (G lambda-1) (Germline immunoglobulin lambda 1)	0.60	0.02
H9KV70		Deleted.	0.27	0.02
P01597	IGKV1-39	Immunoglobulin kappa variable 1-39 (Ig kappa chain V-I region DEE) (Ig kappa chain V-I region Hau) (Ig kappa chain V-I region Mev) (Ig kappa chain V-I region OU) (Ig kappa chain V-I region Walker)	0.47	0.02
P01714	IGLV3-19	Immunoglobulin lambda variable 3-19 (Ig lambda chain V-III region SH)	0.54	0.02
P06331	IGHV4-34	Immunoglobulin heavy variable 4-34 (Ig heavy chain V-II region ARH-77)	0.49	0.02
P19652	ORM2	Alpha-1-acid glycoprotein 2 (AGP 2) (Orosomucoid-2) (OMD 2)	0.20	0.02
P01610		Immunoglobulin kappa variable 1-17 (Ig kappa chain V-I region Gal) (Ig kappa chain V-I region WEA)	0.52	0.02
P01781		Immunoglobulin heavy variable 3-7 (Ig heavy chain V-III region GAL) (Ig heavy chain V-III region GAR) (Ig heavy chain V-III region JON)	0.55	0.02
P02741	CRP	C-reactive protein [Cleaved into: C-reactive protein(1-205)]	0.51	0.02
P01717	IGLV3-25	Immunoglobulin lambda variable 3-25 (Ig lambda chain V-IV region Hil)	0.46	0.02
P01719		Immunoglobulin lambda variable 3-21 (Ig lambda chain V-III region LOI) (Ig lambda chain V-V region DEL) (Ig lambda chain V- VII region MOT)	0.44	0.02

P06681	C2	Complement C2 (EC 3.4.21.43) (C3/C5 convertase) [Cleaved into: Complement C2b	0.15	0.02
Q15848	ADIPOQ	fragment; Complement C2a fragment] Adiponectin (30 kDa adipocyte complement-	-0.23	0.02
		related protein) (Adipocyte complement- related 30 kDa protein) (ACRP30) (Adipocyte, C1q and collagen domain- containing protein) (Adipose most abundant gene transcript 1 protein) (apM-1) (Gelatin-		
		binding protein)		
P04208		Immunoglobulin lambda variable 1-47 (Ig lambda chain V-I region HA) (Ig lambda chain V-I region WAH)	0.53	0.02
Q15485	FCN2	Ficolin-2 (37 kDa elastin-binding protein) (Collagen/fibrinogen domain-containing protein 2) (EBP-37) (Ficolin-B) (Ficolin-beta) (Hucolin) (L-ficolin) (Serum lectin p35)	0.26	0.03
P18135		Immunoglobulin kappa variable 3-20 (Ig kappa chain V-III region B6) (Ig kappa chain V-III region GOL) (Ig kappa chain V-III region HAH) (Ig kappa chain V-III region HIC) (Ig kappa chain V-III region IARC/BL41) (Ig kappa chain V-III region NG9) (Ig kappa chain V-III region SIE) (Ig kappa chain V-III region Ti) (Ig kappa chain V-III region WOL)	0.57	0.03
P01613		Immunoglobulin kappa variable 1D-33 (Ig kappa chain V-I region AG) (Ig kappa chain V-I region Bi) (Ig kappa chain V-I region Lay) (Ig kappa chain V-I region Ni) (Ig kappa chain V-I region Rei) (Ig kappa chain V-I region Roy) (Ig kappa chain V-I region Scw) (Ig kappa chain V-I region WAT)	0.45	0.04
P01602	IGKV1-5	Immunoglobulin kappa variable 1-5 (Ig kappa chain V-I region CAR) (Ig kappa chain V-I region EU) (Ig kappa chain V-I region HK102) (Ig kappa chain V-I region Kue)	0.55	0.04
P04211	IGLV7-43	Immunoglobulin lambda variable 7-43 (Ig lambda chain V region 4A)	0.49	0.04
P01042_2	KNG1	Kininogen-1 (Alpha-2-thiol proteinase inhibitor) (Fitzgerald factor) (High molecular weight kininogen) (HMWK) (Williams-Fitzgerald-Flaujeac factor) [Cleaved into: Kininogen-1 heavy chain; T-kinin (Ile-Ser-Bradykinin); Bradykinin (Kallidin I); Lysylbradykinin (Kallidin II); Kininogen-1 light chain; Low molecular weight growth-promoting factor]	-0.28	0.04
H0YGL9		Deleted.	0.82	0.04
A0M8Q6	IGLC7	Immunoglobulin lambda constant 7 (Ig	0.54	0.05

		lambda-7 chain C region)		
P01617		Immunoglobulin kappa variable 2D-28 (Ig kappa chain V-II region FR) (Ig kappa chain V-II region GM607) (Ig kappa chain V-II region MIL) (Ig kappa chain V-II region TEW)	0.37	0.05
P01620		Immunoglobulin kappa variable 3-20 (Ig kappa chain V-III region B6) (Ig kappa chain V-III region GOL) (Ig kappa chain V-III region HAH) (Ig kappa chain V-III region HIC) (Ig kappa chain V-III region IARC/BL41) (Ig kappa chain V-III region NG9) (Ig kappa chain V-III region SIE) (Ig kappa chain V-III region Ti) (Ig kappa chain V-III region WOL)	0.44	0.05
P01702		Immunoglobulin lambda variable 1-51 (Ig lambda chain V-I region BL2) (Ig lambda chain V-I region EPS) (Ig lambda chain V-I region NEW) (Ig lambda chain V-I region NIG-64)	0.65	0.05
Q6UXB8_2	PI-16	Peptidase inhibitor 16 (PI-16) (Cysteine-rich secretory protein 9) (CRISP-9) (PSP94-binding protein) (CD antigen CD364)	-0.22	0.05
P01876	IGHA1	Immunoglobulin heavy constant alpha 1 (Ig alpha-1 chain C region) (Ig alpha-1 chain C region BUR) (Ig alpha-1 chain C region TRO)	0.51	0.05
P04196	HRG	Histidine-rich glycoprotein (Histidine-proline-rich glycoprotein) (HPRG)	-0.26	0.05
P04433	IGKV3-11	Immunoglobulin kappa variable 3-11 (Ig kappa chain V-III region VG)	0.57	0.05
P06310	IGKV2-30	Immunoglobulin kappa variable 2-30 (Ig kappa chain V-II region RPMI 6410)	0.52	0.05
G8JLA8		Deleted.	0.11	0.07
P01034	CST3	Cystatin-C (Cystatin-3) (Gamma-trace) (Neuroendocrine basic polypeptide) (Postgamma-globulin)	0.16	0.07
P01765		Immunoglobulin heavy variable 3-23 (Ig heavy chain V-III region LAY) (Ig heavy chain V-III region POM) (Ig heavy chain V-III region TEI) (Ig heavy chain V-III region TUR) (Ig heavy chain V-III region VH26) (Ig heavy chain V-III region WAS) (Ig heavy chain V-III region ZAP)	0.49	0.07
P04003	C4BPA	C4b-binding protein alpha chain (C4bp) (Proline-rich protein) (PRP)	0.10	0.07
P01743	IGHV1-46	Immunoglobulin heavy variable 1-46 (Ig heavy chain V-I region DOT) (Ig heavy chain V-I region HG3) (Ig heavy chain V-I region Mot)	0.45	0.07

P01031	C5	Complement C5 (C3 and PZP-like alpha-2-	0.07	0.07
101031	03	macroglobulin domain-containing protein 4)	0.07	0.07
		[Cleaved into: Complement C5 beta chain;		
		Complement C5 alpha chain; C5a		
		anaphylatoxin; Complement C5 alpha' chain]		
P01764	IGHV3-23	Immunoglobulin heavy variable 3-23 (Ig	0.49	0.07
101/04	1011 v 3-23	heavy chain V-III region LAY) (Ig heavy	0.49	0.07
		chain V-III region POM) (Ig heavy chain V-		
		III region TEI) (Ig heavy chain V-III region		
		TIL) (Ig heavy chain V-III region TUR) (Ig		
		heavy chain V-III region VH26) (Ig heavy		
		chain V-III region WAS) (Ig heavy chain V-		
P01766	IGHV3-13	III region ZAP)	0.41	0.07
P01/00	10П V 3-13	Immunoglobulin heavy variable 3-13 (Ig	0.41	0.07
D01767	1011112 52	heavy chain V-III region BRO)	0.21	0.07
P01767	IGHV3-53	Immunoglobulin heavy variable 3-53 (Ig	0.31	0.07
D02740		heavy chain V-III region BUT)	0.12	0.07
P02748	C9	Complement component C9 [Cleaved into:	0.12	0.07
		Complement component C9a; Complement		
006022.2	_	component C9b]	0.12	0.07
Q06033_2		Inter-alpha-trypsin inhibitor heavy chain H3	0.13	0.07
		(ITI heavy chain H3) (ITI-HC3) (Inter-alpha-		
		inhibitor heavy chain 3) (Serum-derived		
	D01.5	hyaluronan-associated protein) (SHAP)	0.1.1	
F5H6I0	B2M	Beta-2-microglobulin	0.14	0.07
P01871	IGHM	Immunoglobulin heavy constant mu (Ig mu	0.44	0.07
		chain C region) (Ig mu chain C region BOT)		
		(Ig mu chain C region GAL) (Ig mu chain C		
		region OU)		
P08571	CD14	Monocyte differentiation antigen CD14	0.13	0.08
		(Myeloid cell-specific leucine-rich		
		glycoprotein) (CD antigen CD14) [Cleaved		
		into: Monocyte differentiation antigen CD14,		
		urinary form; Monocyte differentiation		
		antigen CD14, membrane-bound form]		
O00391_2		Sulfhydryl oxidase 1 (hQSOX) (EC 1.8.3.2)	0.11	0.08
		(Quiescin Q6)		
P04206		Immunoglobulin kappa variable 3-20 (Ig	0.34	0.08
		kappa chain V-III region B6) (Ig kappa chain		
		V-III region GOL) (Ig kappa chain V-III		
		region HAH) (Ig kappa chain V-III region		
		HIC) (Ig kappa chain V-III region		
		IARC/BL41) (Ig kappa chain V-III region		
		NG9) (Ig kappa chain V-III region SIE) (Ig		
		kappa chain V-III region Ti) (Ig kappa chain		
		V-III region WOL)		
P07225	PROS1	Vitamin K-dependent protein S	0.04	0.08
P29622	SERPI4	Kallistatin (Kallikrein inhibitor) (Peptidase	-0.16	0.08
		inhibitor 4) (PI-4) (Serpin A4)		
H0Y755	FCGR3A	Low affinity immunoglobulin gamma Fc	0.18	0.08

		region receptor III-A (Fragment)		
P10643	C7	Complement component C7	0.06	0.08
P01859	IGHG2	Immunoglobulin heavy constant gamma 2 (Ig gamma-2 chain C region) (Ig gamma-2 chain C region DOT) (Ig gamma-2 chain C region TIL) (Ig gamma-2 chain C region ZIE)	0.36	0.09
P01625		Immunoglobulin kappa variable 4-1 (Ig kappa chain V-IV region B17) (Ig kappa chain V-IV region JI) (Ig kappa chain V-IV region Len) (Ig kappa chain V-IV region STH)	0.38	0.09
O75636	FCN3	Ficolin-3 (Collagen/fibrinogen domain- containing lectin 3 p35) (Collagen/fibrinogen domain-containing protein 3) (Hakata antigen)	0.14	0.09
P25311	AZGP1	Zinc-alpha-2-glycoprotein (Zn-alpha-2-GP) (Zn-alpha-2-glycoprotein)	-0.14	0.09
Q96PD5	PGLYRP2	N-acetylmuramoyl-L-alanine amidase (EC 3.5.1.28) (Peptidoglycan recognition protein 2) (Peptidoglycan recognition protein long) (PGRP-L)	-0.14	0.10
P01019	AGT	Angiotensinogen (Serpin A8) [Cleaved into: Angiotensin-1 (Angiotensin 1-10) (Angiotensin I) (Ang I); Angiotensin-2 (Angiotensin 1-8) (Angiotensin II) (Ang II); Angiotensin-3 (Angiotensin 2-8) (Angiotensin III) (Ang III) (Des-Asp[1]-angiotensin II); Angiotensin-4 (Angiotensin 3-8) (Angiotensin IV) (Ang IV); Angiotensin 1-9; Angiotensin 1-7; Angiotensin 1-5; Angiotensin 1-4]	0.21	0.11
P04040	CAT	Catalase (EC 1.11.1.6)	0.18	0.11
P01860	IGHG3	Immunoglobulin heavy constant gamma 3 (HDC) (Heavy chain disease protein) (Ig gamma-3 chain C region)	0.35	0.11
P01611	IGKV1D- 12	Immunoglobulin kappa variable 1D-12 (Ig kappa chain V-I region Wes)	0.30	0.11
P07195	LDHB	L-lactate dehydrogenase B chain (LDH-B) (EC 1.1.1.27) (LDH heart subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46)	0.14	0.11
Q9NZP8	CIRL	Complement C1r subcomponent-like protein (C1r-LP) (C1r-like protein) (EC 3.4.21) (C1r-like serine protease analog protein) (CLSPa)	0.10	0.11
P19823	ITIH2	Inter-alpha-trypsin inhibitor heavy chain H2 (ITI heavy chain H2) (ITI-HC2) (Inter-alpha-inhibitor heavy chain 2) (Inter-alpha-trypsin inhibitor complex component II) (Serum-derived hyaluronan-associated protein) (SHAP)	-0.16	0.12
P01624	IGKV3-15	Immunoglobulin kappa variable 3-15 (Ig kappa chain V-III region CLL) (Ig kappa	0.34	0.13

		chain V-III region POM)		
P02750	LRG1	Leucine-rich alpha-2-glycoprotein (LRG)	0.13	0.13
P20851_2		C4b-binding protein beta chain	0.03	0.13
P07360	C8G	Complement component C8 gamma chain	0.05	0.13
F5GY80	C8B	Complement component C8 beta chain	0.04	0.13
K7ER74	APOC4- APOC2	APOC4-APOC2 readthrough (NMD candidate)	0.24	0.13
P04406_2	111002	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) (Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99)	0.20	0.14
B4E1Z4		cDNA FLJ55673, highly similar to Complement factor B	0.03	0.15
P01011	SERPI3	Alpha-1-antichymotrypsin (ACT) (Cell growth-inhibiting gene 24/25 protein) (Serpin A3) [Cleaved into: Alpha-1-antichymotrypsin His-Pro-less]	0.13	0.15
D6RA08		Deleted.	0.12	0.16
P00915	CA1	Carbonic anhydrase 1 (EC 4.2.1.1) (Carbonate dehydratase I) (Carbonic anhydrase B) (CAB) (Carbonic anhydrase I) (CA-I)	0.10	0.16
P02747	C1QC	Complement C1q subcomponent subunit C	0.12	0.16
H0Y612	TRIM33	E3 ubiquitin-protein ligase TRIM33 (Fragment)	0.15	0.17
P07359	GP1BA	Platelet glycoprotein Ib alpha chain (GP-Ib alpha) (GPIb-alpha) (GPIbA) (Glycoprotein Ibalpha) (Antigen CD42b-alpha) (CD antigen CD42b) [Cleaved into: Glycocalicin]	0.06	0.17
P02749	АРОН	Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding protein) (Anticardiolipin cofactor) (Apolipoprotein H) (Apo-H) (Beta-2-glycoprotein I) (B2GPI) (Beta(2)GPI)	-0.20	0.18
P22792	CPN2	Carboxypeptidase N subunit 2 (Carboxypeptidase N 83 kDa chain) (Carboxypeptidase N large subunit) (Carboxypeptidase N polypeptide 2) (Carboxypeptidase N regulatory subunit)	0.04	0.19
Q6EMK4	VASN	Vasorin (Protein slit-like 2)	0.06	0.19
B7ZKJ8	ITIH4	ITIH4 protein (Inter-alpha-trypsin inhibitor heavy chain H4)	0.11	0.19
O14791_3		Apolipoprotein L1 (Apolipoprotein L) (Apo- L) (ApoL) (Apolipoprotein L-I) (ApoL-I)	0.08	0.19
P02649	APOE	Apolipoprotein E (Apo-E)	0.16	0.19
P55056	APOC4	Apolipoprotein C-IV (Apo-CIV) (ApoC-IV) (Apolipoprotein C4)	0.15	0.19
P05546	SERPIND 1	Heparin cofactor 2 (Heparin cofactor II) (HC-II) (Protease inhibitor leuserpin-2) (HLS2) (Serpin D1)	-0.22	0.19
P06276	BCHE	Cholinesterase (EC 3.1.1.8) (Acylcholine	-0.19	0.21

		acylhydrolase) (Butyrylcholine esterase)		
P48740	MASP1	(Choline esterase II) (Pseudocholinesterase) Mannan-binding lectin serine protease 1 (EC	0.04	0.23
		3.4.21) (Complement factor MASP-3)		
		(Complement-activating component of Ra-		
		reactive factor) (Mannose-binding lectin-		
		associated serine protease 1) (MASP-1)		
		(Mannose-binding protein-associated serine		
		protease) (Ra-reactive factor serine protease		
		p100) (RaRF) (Serine protease 5) [Cleaved		
		into: Mannan-binding lectin serine protease 1		
		heavy chain; Mannan-binding lectin serine		
P20742	PZP	protease 1 light chain]	0.12	0.25
P20742	PZP	Pregnancy zone protein (C3 and PZP-like	0.12	0.25
		alpha-2-macroglobulin domain-containing protein 6)		
P02766	TTR	 	-0.18	0.27
		Transthyretin (ATTR) (Prealbumin) (TBPA) Peroxiredoxin-2 (EC 1.11.1.15) (Natural		
P32119	PRDX2	` ' `	0.02	0.30
		killer cell-enhancing factor B) (NKEF-B)		
		(PRP) (Thiol-specific antioxidant protein) (TSA) (Thioredoxin peroxidase 1)		
		· · · · · · · · · · · · · · · · · · ·		
P01833	PIGR	(Thioredoxin-dependent peroxide reductase 1)	0.25	0.30
P01833	PIOK	Polymeric immunoglobulin receptor (PIgR)	0.23	0.50
		(Poly-Ig receptor) (Hepatocellular carcinoma-		
		associated protein TB6) [Cleaved into:		
P02745	C1QA	Secretory component] Complement C1q subcomponent subunit A	0.11	0.31
P19320_3	CIQA	Vascular cell adhesion protein 1 (V-CAM 1)	0.11	0.31
P19320_3		(VCAM-1) (INCAM-100) (CD antigen	0.13	0.51
		CD106)		
P22352	GPX3	Glutathione peroxidase 3 (GPx-3) (GSHPx-3)	-0.07	0.32
1 22332	GI AS	(EC 1.11.1.9) (Extracellular glutathione	-0.07	0.32
		peroxidase) (Plasma glutathione peroxidase)		
		(GPx-P) (GSHPx-P)		
Q08380	LGALS3B	Galectin-3-binding protein (Basement	0.14	0.32
200200	P	membrane autoantigen p105) (Lectin	0.1.	0.02
	_	galactoside-binding soluble 3-binding protein)		
		(Mac-2-binding protein) (MAC2BP) (Mac-2		
		BP) (Tumor-associated antigen 90K)		
P12259	F5	Coagulation factor V (Activated protein C	0.03	0.32
		cofactor) (Proaccelerin, labile factor)		
		[Cleaved into: Coagulation factor V heavy		
		chain; Coagulation factor V light chain]		
P07900	HSP90AA	Heat shock protein HSP 90-alpha (Heat shock	0.14	0.34
	1	86 kDa) (HSP 86) (HSP86)		
		(Lipopolysaccharide-associated protein 2)		
		(LAP-2) (LPS-associated protein 2) (Renal		
		carcinoma antigen NY-REN-38)		
P05452	CLEC3B	Tetranectin (TN) (C-type lectin domain	-0.14	0.35
		family 3 member B) (Plasminogen kringle 4-		

		binding protein)		
P19827	ITIH1	Inter-alpha-trypsin inhibitor heavy chain H1 (ITI heavy chain H1) (ITI-HC1) (Inter-alpha-	-0.13	0.36
		inhibitor heavy chain 1) (Inter-alpha-trypsin		
		inhibitor complex component III) (Serum-		
		derived hyaluronan-associated protein)		
		(SHAP)		
O43866	CD5L	CD5 antigen-like (Apoptosis inhibitor	0.24	0.37
		expressed by macrophages) (hAIM) (CT-2)		
		(IgM-associated peptide) (SP-alpha)		
P00918	CA2	Carbonic anhydrase 2 (EC 4.2.1.1) (Carbonate	-0.03	0.37
		dehydratase II) (Carbonic anhydrase C)		
		(CAC) (Carbonic anhydrase II) (CA-II)		
P04075	ALDOA	Fructose-bisphosphate aldolase A (EC	0.10	0.39
		4.1.2.13) (Lung cancer antigen NY-LU-1)		
D07057		(Muscle-type aldolase)	0.01	
P07357	C8A	Complement component C8 alpha chain	-0.01	0.39
11037512	CD 44	(Complement component 8 subunit alpha)	0.01	0.41
H0YD13	CD44	CD44 antigen	-0.01	0.41
P02751_10		Fibronectin (FN) (Cold-insoluble globulin)		0.41
		(CIG) [Cleaved into: Anastellin; Ugl-Y1;		
D01977	IGHA2	Ugl-Y2; Ugl-Y3]	0.22	0.41
P01877	IGHA2	Immunoglobulin heavy constant alpha 2 (Ig	0.32	0.41
		alpha-2 chain C region) (Ig alpha-2 chain C region BUT) (Ig alpha-2 chain C region LAN)		
P01042	KNG1	Kininogen-1 (Alpha-2-thiol proteinase	-0.15	0.42
101042	KNOI	inhibitor) (Fitzgerald factor) (High molecular	-0.13	0.42
		weight kininogen) (HMWK) (Williams-		
		Fitzgerald-Flaujeac factor) [Cleaved into:		
		Kininogen-1 heavy chain; T-kinin (Ile-Ser-		
		Bradykinin); Bradykinin (Kallidin I); Lysyl-		
		bradykinin (Kallidin II); Kininogen-1 light		
		chain; Low molecular weight growth-		
		promoting factor]		
B0YIW2	APOC3	Apolipoprotein C-III (Apolipoprotein C-III	0.17	0.43
		variant 1)		
E7EPZ9		Deleted.	0.05	0.43
P04114	APOB	Apolipoprotein B-100 (Apo B-100) [Cleaved	0.06	0.43
		into: Apolipoprotein B-48 (Apo B-48)]		
P51884	LUM	Lumican (Keratan sulfate proteoglycan	-0.14	0.43
		lumican) (KSPG lumican)		
Q5VY30	RBP4	Retinol-binding protein	-0.11	0.43
Q9Y5Y7	LYVE1	Lymphatic vessel endothelial hyaluronic acid	0.14	0.44
		receptor 1 (LYVE-1) (Cell surface retention		
		sequence-binding protein 1) (CRSBP-1)		
		(Extracellular link domain-containing protein		
D04264	IZDT1	1) (Hyaluronic acid receptor)	0.10	0.44
P04264	KRT1	Keratin, type II cytoskeletal 1 (67 kDa	0.18	0.44
	<u>j</u>	cytokeratin) (Cytokeratin-1) (CK-1) (Hair	<u>_</u>	

		alpha protein) (Keratin-1) (K1) (Type-II keratin Kb1)		
P04004	VTN	Vitronectin (VN) (S-protein) (Serum- spreading factor) (V75) [Cleaved into: Vitronectin V65 subunit; Vitronectin V10 subunit; Somatomedin-B]	0.01	0.46
C9JF17	APOD	Apolipoprotein D (Fragment)	-0.12	0.46
Q16610	ECM1	Extracellular matrix protein 1 (Secretory component p85)	0.03	0.46
B1AKG0	CFHR1	Complement factor H-related protein 1	0.08	0.47
P02679_2		Fibrinogen gamma chain	0.16	0.48
P01591	JCHAIN	Immunoglobulin J chain (Joining chain of multimeric IgA and IgM)	0.21	0.49
P35542	SAA4	Serum amyloid A-4 protein (Constitutively expressed serum amyloid A protein) (C-SAA)	-0.07	0.50
P02675	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	0.15	0.51
G3V2W1	SERPI10	Protein Z-dependent protease inhibitor (Serpin peptidase inhibitor, clade A (Alpha-1 antiproteinase, antitrypsin), member 10, isoform CRA_a)	0.03	0.51
P01008	SERPINC 1	Antithrombin-III (ATIII) (Serpin C1)	-0.11	0.51
P60709	ACTB	Actin, cytoplasmic 1 (Beta-actin) [Cleaved into: Actin, cytoplasmic 1, N-terminally processed]	0.07	0.53
P15151_3		Poliovirus receptor (Nectin-like protein 5) (NECL-5) (CD antigen CD155)	0.02	0.54
P61626	LYZ	Lysozyme C (EC 3.2.1.17) (1,4-beta-N-acetylmuramidase C)	0.11	0.54
V9GYE7	CFHR2	Complement factor H-related protein 2	0.02	0.54
G3XAM2	CFI	Complement factor I (Complement factor I, isoform CRA_b)	-0.03	0.55
P69905	HBA1	Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain)	0.00	0.55
P69905	HBA2	Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain)	0.00	0.55
O95445	APOM	Apolipoprotein M (Apo-M) (ApoM) (Protein G3a)	-0.08	0.55
P02790	HPX	Hemopexin (Beta-1B-glycoprotein)	-0.10	0.56
P68871	НВВ	Hemoglobin subunit beta (Beta-globin) (Hemoglobin beta chain) [Cleaved into: LVV-hemorphin-7; Spinorphin]	0.01	0.60
P00747	PLG	Plasminogen (EC 3.4.21.7) [Cleaved into: Plasmin heavy chain A; Activation peptide; Angiostatin; Plasmin heavy chain A, short form; Plasmin light chain B]	-0.09	0.61
P00748	F12	Coagulation factor XII (EC 3.4.21.38) (Hageman factor) (HAF) [Cleaved into:	0.02	0.61

		Coagulation factor XIIa heavy chain; Beta-		
		factor XIIa part 1; Coagulation factor XIIa light chain (Beta-factor XIIa part 2)]		
Q92954_4		Proteoglycan 4 (Lubricin) (Megakaryocyte-	-0.10	0.61
		stimulating factor) (Superficial zone		
		proteoglycan) [Cleaved into: Proteoglycan 4		
		C-terminal part]		
P01023	A2M	Alpha-2-macroglobulin (Alpha-2-M) (C3 and	-0.06	0.63
		PZP-like alpha-2-macroglobulin domain-		
		containing protein 5)		
P06396	GSN	Gelsolin (AGEL) (Actin-depolymerizing	-0.08	0.67
		factor) (ADF) (Brevin)		
P0DJI8	SAA1	Serum amyloid A-1 protein (SAA) [Cleaved	0.11	0.68
		into: Amyloid protein A (Amyloid fibril		
		protein AA); Serum amyloid protein A(2-		
		104); Serum amyloid protein A(3-104);		
		Serum amyloid protein A(2-103); Serum		
		amyloid protein A(2-102); Serum amyloid		
D22001	PROZ	protein A(4-101)]	0.05	0.69
P22891		Vitamin K-dependent protein Z	-0.05	0.68
P27169	PON1	Serum paraoxonase/arylesterase 1 (PON 1) (EC 3.1.1.2) (EC 3.1.1.81) (EC 3.1.8.1)	-0.17	0.69
		(Aromatic esterase 1) (A-esterase 1) (K-45)		
D6RF35	GC	(Serum aryldialkylphosphatase 1)	-0.09	0.69
		Vitamin D-binding protein	 	
K7ERG9	CFD	Complement factor D	0.02	0.72
P00742	F10	Coagulation factor X (EC 3.4.21.6) (Stuart	0.03	0.72
		factor) (Stuart-Prower factor) [Cleaved into:		
		Factor X light chain; Factor X heavy chain; Activated factor Xa heavy chain]		
P01024	C3	Complement C3 (C3 and PZP-like alpha-2-	-0.08	0.72
F01024	C3	macroglobulin domain-containing protein 1)	-0.08	0.72
		[Cleaved into: Complement C3 beta chain;		
		C3-beta-c (C3bc); Complement C3 alpha		
		chain; C3a anaphylatoxin; Acylation		
		stimulating protein (ASP) (C3adesArg);		
		Complement C3b alpha' chain; Complement		
		C3c alpha' chain fragment 1; Complement		
		C3dg fragment; Complement C3g fragment;		
		Complement C3d fragment; Complement C3f		
		fragment; Complement C3c alpha' chain		
		fragment 2]		
P01861	IGHG4	Immunoglobulin heavy constant gamma 4 (Ig	0.06	0.72
		gamma-4 chain C region)		
P02042	HBD	Hemoglobin subunit delta (Delta-globin)	-0.03	0.72
		(Hemoglobin delta chain)		
P02760	AMBP	Protein AMBP [Cleaved into: Alpha-1-	-0.10	0.72
		microglobulin (Protein HC) (Alpha-1		
		microglycoprotein) (Complex-forming		
	1	glycoprotein heterogeneous in charge); Inter-		

		alpha-trypsin inhibitor light chain (ITI-LC)		
		(Bikunin) (EDC1) (HI-30) (Uronic-acid-rich protein); Trypstatin]		
P02765	AHSG	Alpha-2-HS-glycoprotein (Alpha-2-Z-	-0.07	0.72
102703	Miso	globulin) (Ba-alpha-2-glycoprotein) (Fetuin-	-0.07	0.72
		A) [Cleaved into: Alpha-2-HS-glycoprotein		
		chain A; Alpha-2-HS-glycoprotein chain B]		
P08185	SERPI6	Corticosteroid-binding globulin (CBG)	0.00	0.72
		(Serpin A6) (Transcortin)		
P0C0L5	C4B	Complement C4-B (Basic complement C4)	-0.01	0.72
		(C3 and PZP-like alpha-2-macroglobulin		
		domain-containing protein 3) [Cleaved into:		
		Complement C4 beta chain; Complement C4-		
		B alpha chain; C4a anaphylatoxin; C4b-B;		
		C4d-B; Complement C4 gamma chain]		
P0C0L5	C4B_2	Complement C4-B (Basic complement C4)	-0.01	0.72
		(C3 and PZP-like alpha-2-macroglobulin		
		domain-containing protein 3) [Cleaved into:		
		Complement C4 beta chain; Complement C4-		
		B alpha chain; C4a anaphylatoxin; C4b-B;		
		C4d-B; Complement C4 gamma chain]		
Q9UGM5	FETUB	Fetuin-B (16G2) (Fetuin-like protein IRL685)	-0.12	0.72
D4E2C7	_	(Gugu)	0.00	0.74
B4E2S7		cDNA FLJ58780, highly similar to Homo sapiens lysosomal-associated membrane	0.00	0.74
		protein 2 (LAMP2), transcript variant		
		LAMP2B, mRNA		
E9PFZ2	СР	Ceruloplasmin	0.11	0.74
F5GXS5	İ	Deleted.	0.04	0.74
P14151	SELL	L-selectin (CD62 antigen-like family member	0.01	0.74
		L) (Leukocyte adhesion molecule 1) (LAM-1)		
		(Leukocyte surface antigen Leu-8)		
		(Leukocyte-endothelial cell adhesion		
		molecule 1) (LECAM1) (Lymph node		
		homing receptor) (TQ1) (gp90-MEL) (CD		
		antigen CD62L)		
P36955	SERPINF	Pigment epithelium-derived factor (PEDF)	0.00	0.74
	1	(Cell proliferation-inducing gene 35 protein)		
		(EPC-1) (Serpin F1)		
Q04756	HGFAC	Hepatocyte growth factor activator (HGF	-0.02	0.74
		activator) (HGFA) (EC 3.4.21) [Cleaved		
		into: Hepatocyte growth factor activator short		
		chain; Hepatocyte growth factor activator		
D05542	CEDDIA	long chain]	0.00	0.77
P05543	SERPI7	Thyroxine-binding globulin (Serpin A7) (T4-binding globulin)	-0.08	0.77
F8W1Q3		binding globulin) Biotinidase (Biotinase) (EC 3.5.1.12)	-0.01	0.78
			· -	
O75882_3	CEDDING	Attractin (DPPT-L) (Mahogany homolog)	-0.02	$\frac{0.78}{0.78}$
P05155	SERPING	Plasma protease C1 inhibitor (C1 Inh)	0.02	0.78

	1	(C1Inh) (C1 esterase inhibitor) (C1-inhibiting		
000	CDD 2	factor) (Serpin G1)	0.04	
Q96IY4	CPB2	Carboxypeptidase B2 (EC 3.4.17.20)	-0.04	0.78
		(Carboxypeptidase U) (CPU) (Plasma		
		carboxypeptidase B) (pCPB) (Thrombin-		
D0500 6	ELID C1	activable fibrinolysis inhibitor) (TAFI)	0.00	
P07996	THBS1	Thrombospondin-1 (Glycoprotein G)	-0.08	0.79
P08603	CFH	Complement factor H (H factor 1)	0.01	0.79
P10909_4		Clusterin (Aging-associated gene 4 protein)	-0.04	0.82
		(Apolipoprotein J) (Apo-J) (Complement		
		cytolysis inhibitor) (CLI) (Complement-		
		associated protein SP-40,40) (Ku70-binding		
		protein 1) (NA1/NA2) (Sulfated glycoprotein		
		2) (SGP-2) (Testosterone-repressed prostate		
		message 2) (TRPM-2) [Cleaved into:		
		Clusterin beta chain (ApoJalpha)		
		(Complement cytolysis inhibitor a chain);		
		Clusterin alpha chain (ApoJbeta)		
		(Complement cytolysis inhibitor b chain)]		
I3L145	SHBG	Sex hormone-binding globulin (Sex hormone-	-0.08	0.83
		binding globulin, isoform CRA_a)		
K7ERI9	APOC1	Apolipoprotein C-I (Fragment)	0.09	0.83
P00736	C1R	Complement C1r subcomponent (EC	-0.05	0.83
		3.4.21.41) (Complement component 1		
		subcomponent r) [Cleaved into: Complement		
		C1r subcomponent heavy chain; Complement		
		C1r subcomponent light chain]		
P02775	PPBP	Platelet basic protein (PBP) (C-X-C motif	-0.08	0.83
		chemokine 7) (Leukocyte-derived growth		
		factor) (LDGF) (Macrophage-derived growth		
		factor) (MDGF) (Small-inducible cytokine		
		B7) [Cleaved into: Connective tissue-		
		activating peptide III (CTAP-III) (LA-PF4)		
		(Low-affinity platelet factor IV); TC-2;		
		Connective tissue-activating peptide III(1-81)		
		(CTAP-III(1-81)); Beta-thromboglobulin		
		(Beta-TG); Neutrophil-activating peptide		
		2(74) (NAP-2(74)); Neutrophil-activating		
		peptide 2(73) (NAP-2(73)); Neutrophil-		
		activating peptide 2 (NAP-2); TC-1;		
		Neutrophil-activating peptide 2(1-66) (NAP-		
		2(1-66)); Neutrophil-activating peptide 2(1-		
0.1.0.1.0.0	~~~	63) (NAP-2(1-63))]		
Q13103	SPP2	Secreted phosphoprotein 24 (Spp-24)	-0.02	0.83
DOCOL 4		(Secreted phosphoprotein 2)	0.02	0.04
P0C0L4	C4A	Complement C4-A (Acidic complement C4)	0.02	0.84
		(C3 and PZP-like alpha-2-macroglobulin		
		domain-containing protein 2) [Cleaved into:		
		Complement C4 beta chain; Complement C4-		
		A alpha chain; C4a anaphylatoxin; C4b-A;		


dase N catalytic chain (CPN) (Anaphylatoxin inactivator) coxypeptidase) idase N polypeptide 1) idase N small subunit) Lysine carboxypeptidase) oxypeptidase B) (Serum lase N) (SCPN) llasmin (Alpha-2-AP) (Alpha-2- itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation nt chain; Coagulation factor IXa	0.85 0.85 0.85 0.90 0.90
(Anaphylatoxin inactivator) boxypeptidase) idase N polypeptide 1) idase N small subunit) Lysine carboxypeptidase) bxypeptidase B) (Serum lase N) (SCPN) llasmin (Alpha-2-AP) (Alpha-2- itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.85
boxypeptidase) idase N polypeptide 1) idase N small subunit) Lysine carboxypeptidase) oxypeptidase B) (Serum lase N) (SCPN) clasmin (Alpha-2-AP) (Alpha-2-itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
idase N polypeptide 1) idase N small subunit) (Lysine carboxypeptidase) oxypeptidase B) (Serum lase N) (SCPN) lasmin (Alpha-2-AP) (Alpha-2- itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
idase N small subunit) Lysine carboxypeptidase) oxypeptidase B) (Serum lase N) (SCPN) clasmin (Alpha-2-AP) (Alpha-2- itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
Lysine carboxypeptidase) Exypeptidase B) (Serum Ilase N) (SCPN) Ilasmin (Alpha-2-AP) (Alpha-2- itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
oxypeptidase B) (Serum lase N) (SCPN) clasmin (Alpha-2-AP) (Alpha-2- citor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
lase N) (SCPN) lasmin (Alpha-2-AP) (Alpha-2- itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) actor IX (EC 3.4.21.22) ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
lasmin (Alpha-2-AP) (Alpha-2- itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) -0.04 actor IX (EC 3.4.21.22) -0.01 ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
itor) (Alpha-2-PI) (Serpin F2) rein (Fragment) -0.04 actor IX (EC 3.4.21.22) -0.01 ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
rein (Fragment) -0.04 actor IX (EC 3.4.21.22) -0.01 ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	
actor IX (EC 3.4.21.22) -0.01 ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	
ctor) (Plasma thromboplastin PTC) [Cleaved into: Coagulation	0.90
PTC) [Cleaved into: Coagulation	
nt chain; Coagulation factor IXa	
choline-sterol acyltransferase -0.01	0.90
	0.93
	0.94
· · · · · · · · · · · · · · · · · · ·	
	1.00
1 \	
-	
	1.00
	1.00
	1.00
coprotein (Alpha-1-B -0.02	1.00
n A-IV (Apo-AIV) (ApoA-IV) 0.00	1.00
	1.00
	1.00
	1.00
	(Lecithin-cholesterol de) (Phospholipid-cholesterol de) related protein dd P-component (SAP) (9.5S dprotein) [Cleaved into: Serum mponent(1-203)] C1s subcomponent (EC 1 esterase) (Complement subcomponent s) [Cleaved into: C1s subcomponent light chain] n (EC 1.16.3.1) (Ferroxidase) (EC 3.4.21.5) (Coagulation daved into: Activation peptide activation peptide fragment 2; de chain; Thrombin heavy chain] nding protein (DBP) (VDB) (Gc de macrophage activating factor) de MAF) (Gc-globulin) (Group- donent) (Gc) (Vitamin D-binding dophage activating factor) (DBP- de proportion (Alpha-1-B de protein (Alpha-1-B de prote


1 0	globin) (Hb F Agamma) (Hemoglobin gamma-1 chain) (Hemoglobin gamma-A	
С	chain)	

688

689


*log fold change - positive value for log fold change indicate higher enrichment in HIV(+); of alse-discovery rate adjusted after logistic regression using inverse probability weighting accounting for recruitment site, sex , age, HIV status, mid-upper arm circumference, and presence of oedema





-20

z-score



-20

z-score

